ロード中...
Bispecific antibodies in cancer immunotherapy
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeu...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2018-02-01
|
| シリーズ: | Therapeutic Advances in Vaccines and Immunotherapy |
| オンライン･アクセス: | https://doi.org/10.1177/2515135518763280 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|